Harvoni Rebates In Massachusetts Aim For Access, Not Savings
This article was originally published in The Pink Sheet Daily
Executive Summary
Deeper discount gets Gilead exclusive formulary position with no restrictions on 'medical necessity' while MassHealth gets to treat more patients for the same cost.
You may also be interested in...
CMS Wants To Facilitate Value-Based Discounts For HCV Drugs In Medicaid
CMS requests information from hepatitis C manufacturers on how value-based purchasing arrangements might work in Medicaid. Agency also urges state Medicaid directors to relax overly strict coverage requirements for the drugs.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.